+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Vaccine Market Size, Share & Trends Analysis Report By Indication Type (Bladder, Cervical), By Vaccine Type (Preventive, Therapeutic), By Technology Type (Recombinant, Whole-cell), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 130 Pages
  • July 2023
  • Region: Global
  • Grand View Research
  • ID: 5853863
The global cancer vaccine market size is expected to reach USD 16.84 billion by 2030, expanding at a CAGR of 11.04% from 2023 to 2030. The market growth is attributed to the increasing prevalence of cancer among the population. According to the WHO, it is a leading cause of death globally, which accounted for 10 million deaths in 2020, with prostate, lung, breast, colon, skin, and stomach cancers being the most common types causing one in every six deaths worldwide. A rise in the number of cases can be majorly attributed to various factors, such as the rising geriatric population and changing prevalence of certain causes of cancer associated with economic & social development. This is particularly seen in emerging economies, wherein a general shift is observed in terms of cancers associated with poverty, which is a contrast to developed economies, wherein cases have increasingly been associated with lifestyle disorders.

According to the WHO, obesity, certain types of infections, and exposure to radiation are major factors associated with an increase in the number of cases. Moreover, the demand for vaccines is significantly increasing worldwide owing to technological advancements in the field of prevention. FDA support for developing biomarkers & mass cytometry; launch of various flow cytometry reagents for drug discovery & diagnosis; technologically advanced miniaturized devices, facilitating portability & precision; development of cell- & bead-based flow cytometry techniques are major factors boosting the market growth. Various programs to increase awareness about cancer by organizations are key factors responsible for the increased demand for innovative vaccines worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, CDC, WHO, the U.S. Preventive Services Task Force, and others for increasing screening of cervical cancer are major factors expected to augment the market growth during the forecast period.

Furthermore, key players involved in developing and formulating various vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the industry. Moreover, several players are involved in the development of novel vaccines to meet the rising demand for prevention of the condition. For instance, in February 2023, BioNTech announced plans to proceed with clinical trials for its vaccine from September 2023, which is expected to be launched in the market before 2030. In March 2023, Researchers at Cleveland Clinic announced the next step toward the launch of a vaccine for the prevention of triple-negative breast cancer, which is one of the most lethal forms of the condition.

Cancer Vaccine Market Report Highlights

  • The preventive vaccine type segment held the largest revenue share in 2022 owing to the need for preventing the condition due to the rising prevalence
  • The cervical cancer indication type segment is expected to register the fastest growth rate over the forecast period due to the rising disease prevalence
  • On the basis of technology type, the recombinant vaccine segment dominated the global industry in 2022 due to the high availability of vaccines developed from recombinant technology
  • Key players operating are constantly focusing on product launches and geographical expansions to maintain their market position and share
  • North America held the largest revenue share in 2022 on account of the better healthcare infrastructure, the high prevalence of cancer, the presence of key players, and the availability of proper vaccination service

Table of Contents

Chapter 1 Cancer Vaccine Market: Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Vaccine Type Segment
1.1.1.2 Technology type segment
1.1.1.3 Indication type segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 The Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Cancer Vaccine Market: Executive Summary
2.1 Market Snapshot
2.2 Vaccine Type and Indication Type Snapshot
2.3 Technology Type Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Cancer Vaccine Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Increasing Prevalence of cancer
3.3.1.2 Growing investments and governmental funding in the development of cancer vaccines
3.3.1.3 Increasing demand for cancer vaccines
3.3.1.4 Launch of new cancer vaccines
3.3.2 Market Restraint Analysis
3.3.2.1 Complex And Time-Consuming Regulatory Approval Process
3.3.2.2 High Price Associated With Vaccines
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Cancer Vaccine Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Cancer Vaccine Market: Vaccine Type Business Analysis
5.1 Definition And Scope
5.2 Vaccine Type Market Share Analysis, 2022 & 2030
5.3 Global Cancer Vaccine Market, By Vaccine Type, 2018 To 2030
5.4 Cancer Vaccine Market: Vaccine Type Movement Analysis
5.5 Preventive Cancer Vaccines
5.5.1 Preventive Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.6 Therapeutic Cancer Vaccines
5.6.1 Therapeutic Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.7 Others
5.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Cancer Vaccine Market: Indication Type Business Analysis
6.1 Definition And Scope
6.2 Indication Type Market Share Analysis, 2022 & 2030
6.3 Global Cancer Vaccine Market, By Indication Type, 2018 To 2030
6.4 Cancer Vaccine Market: Indication Type Movement Analysis
6.5 Prostate Cancer
6.5.1 Prostate Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.6 Bladder Cancer
6.6.1 Bladder Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.7 Melanoma
6.7.1 Melanoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.8 Cervical Cancer
6.8.1 Cervical Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.9 Others
6.9.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Cancer Vaccine Market: Technology Type Business Analysis
7.1 Definition And Scope
7.2 Technology Type Market Share Analysis, 2022 & 2030
7.3 Global Cancer Vaccine Market, By Technology Type, 2018 To 2030
7.4 Cancer Vaccine Market: Technology Type Movement Analysis
7.5 Recombinant Cancer Vaccines
7.5.1 Recombinant Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6 Whole-Cell Cancer Vaccines
7.6.1 Whole-Cell Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.7 Viral Vector And Dna Cancer Vaccines
7.7.1 Viral Vector And Dna Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.8 Others
7.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Cancer Vaccine Market: Regional Business Analysis
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2022 & 2030
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Latin America
8.5.5 Mea
8.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
8.7 North America
8.7.1 North America Cancer Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.7.2 U.S.
8.7.2.1 U.S. Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.7.2.2 Key Country Dynamics
8.7.2.3 Regulatory Framework
8.7.2.4 Competitive Scenario
8.7.3 Canada
8.7.3.1 Canada Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.7.3.2 Key Country Dynamics
8.7.3.3 Regulatory Framework
8.7.3.4 Competitive Scenario
8.8 Europe
8.8.1 Europe Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.2 UK
8.8.2.1 UK Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.2.2 Key Country Dynamics
8.8.2.3 Regulatory Framework
8.8.2.4 Competitive Scenario
8.8.3 Germany
8.8.3.1 Germany Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.3.2 Key Country Dynamics
8.8.3.3 Regulatory Framework
8.8.3.4 Competitive Scenario
8.8.4 Spain
8.8.4.1 Spain Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.4.2 Key Country Dynamics
8.8.4.3 Regulatory Framework
8.8.4.4 Competitive Scenario
8.8.5 France
8.8.5.1 France Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.5.2 Key Country Dynamics
8.8.5.3 Regulatory Framework
8.8.5.4 Competitive Scenario
8.8.6 Italy
8.8.6.1 Italy Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.6.2 Key Country Dynamics
8.8.6.3 Regulatory Framework
8.8.6.4 Competitive Scenario
8.8.7 Norway
8.8.7.1 Norway Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.7.3 Regulatory Framework
8.8.7.4 Competitive Scenario
8.8.8 Denmark
8.8.8.1 Denmark Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.8.2 Key Country Dynamics
8.8.8.3 Regulatory Framework
8.8.8.4 Competitive Scenario
8.8.9 Sweden
8.8.9.1 Sweden Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.8.9.2 Key Country Dynamics
8.8.9.3 Regulatory Framework
8.8.9.4 Competitive Scenario
8.9 Asia Pacific
8.9.1 Asia-Pacific Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.2 Japan
8.9.2.1 Japan Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.2.2 Key Country Dynamics
8.9.2.3 Regulatory Framework
8.9.2.4 Competitive Scenario
8.9.3 China
8.9.3.1 China Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.3.2 Key Country Dynamics
8.9.3.3 Regulatory Framework
8.9.3.4 Competitive Scenario
8.9.4 India
8.9.4.1 India Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.4.2 Key Country Dynamics
8.9.4.3 Regulatory Framework
8.9.4.4 Competitive Scenario
8.9.5 South Korea
8.9.5.1 South Korea Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.5.2 Key Country Dynamics
8.9.5.3 Regulatory Framework
8.9.5.4 Competitive Scenario
8.9.6 Thailand
8.9.6.1 Thailand Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.6.2 Key Country Dynamics
8.9.6.3 Regulatory Framework
8.9.6.4 Competitive Scenario
8.9.7 Australia
8.9.7.1 Australia Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.9.7.2 Key Country Dynamics
8.9.7.3 Regulatory Framework
8.9.7.4 Competitive Scenario
8.10 Latin America
8.10.1 Latin America Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.10.2 Brazil
8.10.2.1 Brazil Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.10.2.2 Key Country Dynamics
8.10.2.3 Regulatory Framework
8.10.2.4 Competitive Scenario
8.10.3 Mexico
8.10.3.1 Mexico Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.10.3.2 Key Country Dynamics
8.10.3.3 Regulatory Framework
8.10.3.4 Competitive Scenario
8.10.4 Argentina
8.10.4.1 Argentina Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.10.4.2 Key Country Dynamics
8.10.4.3 Regulatory Framework
8.10.4.4 Competitive Scenario
8.11 MEA
8.11.1 MEA Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.11.2 South Africa
8.11.2.1 South Africa Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.11.2.2 Key Country Dynamics
8.11.2.3 Regulatory Framework
8.11.2.4 Competitive Scenario
8.11.3 Saudi Arabia
8.11.3.1 Saudi Arabia Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.11.3.2 Key Country Dynamics
8.11.3.3 Regulatory Framework
8.11.3.4 Competitive Scenario
8.11.4 UAE
8.11.4.1 UAE Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.11.4.2 Key Country Dynamics
8.11.4.3 Regulatory Framework
8.11.4.4 Competitive Scenario
8.11.5 Kuwait
8.11.5.1 Kuwait Cancer Vaccine Market, 2018 - 2030 (USD Million)
8.11.5.2 Key Country Dynamics
8.11.5.3 Regulatory Framework
8.11.5.4 Competitive Scenario
Chapter 9 Cancer Vaccine Market: Company Profiling
9.1 Company Categorization
9.2 Strategy Mapping
9.2.1 New Product Launch
9.2.2 Partnerships
9.2.3 Acquisition
9.2.4 Collaboration
9.2.5 Funding
9.3 Key Company Market Share Analysis, 2022
9.4 Company Profiles
9.4.1 Merck & Co., Inc.
9.4.1.1 Company Overview
9.4.1.2 Financial Performance
9.4.1.3 Product Benchmarking
9.4.1.4 Strategic Initiatives
9.4.2 GSK plc
9.4.2.1 Company Overview
9.4.2.2 Financial Performance
9.4.2.3 Product Benchmarking
9.4.2.4 Strategic Initiatives
9.4.3 Dendreon Pharmaceuticals LLC.
9.4.3.1 Company Overview
9.4.3.2 Product Benchmarking
9.4.3.3 Strategic Initiatives
9.4.4 Dynavax Technologies.
9.4.4.1 Company Overview
9.4.4.2 Financial Performance
9.4.4.3 Product Benchmarking
9.4.4.4 Strategic Initiatives
9.4.5 Ferring B.V.
9.4.5.1 Company Overview
9.4.5.2 Financial Performance
9.4.5.3 Product Benchmarking
9.4.5.4 Strategic Initiatives
9.4.6 Amgen, Inc.
9.4.6.1 Company Overview
9.4.6.2 Financial Performance
9.4.6.3 Product Benchmarking
9.4.6.4 Strategic Initiatives
9.4.7 Moderna, Inc.
9.4.7.1 Company Overview
9.4.7.2 Financial Performance
9.4.7.3 Product Benchmarking
9.4.7.4 Strategic Initiatives
9.4.8 Sanofi
9.4.8.1 Company Overview
9.4.8.2 Financial Performance
9.4.8.3 Product Benchmarking
9.4.9.4 Strategic Initiatives
9.4.9 AstraZeneca
9.4.9.1 Company Overview
9.4.9.2 Financial Performance
9.4.9.3 Product Benchmarking
9.4.9.4 Strategic Initiatives
9.4.10 Bristol-Myers Squibb Company
9.4.9.1 Company Overview
9.4.9.2 Financial Performance
9.4.9.3 Product Benchmarking
9.4.9.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Cancer Vaccine Market, By Region, 2018 - 2030 (USD Million)
Table 4 Global Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 5 Global Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 6 Global Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 7 North America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 9 North America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 10 North America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 11 U.S. Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 12 U.S. Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 13 U.S. Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 14 Canada Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 15 Canada Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 16 Canada Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 17 Europe Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 18 Europe Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 19 Europe Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 20 Europe Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 21 UK Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 22 UK Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 23 UK Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 24 Germany Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 25 Germany Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 26 Germany Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 27 France Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 28 France Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 29 France Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 30 Italy Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 31 Italy Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 32 Italy Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 33 Spain Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 34 Spain Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 35 Spain Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 36 Denmark Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 37 Denmark Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 38 Denmark Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 39 Sweden Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 40 Sweden Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 41 Sweden Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 42 Norway Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 43 Norway Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 44 Norway Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 49 Japan Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 50 Japan Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 51 Japan Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 52 China Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 53 China Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 54 China Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 55 India Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 56 India Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 57 India Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 58 South Korea Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 59 South Korea Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 60 South Korea Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 61 Australia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 62 Australia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 63 Australia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 64 Thailand Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 65 Thailand Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 66 Thailand Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 67 Latin America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 68 Latin America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 69 Latin America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 70 Latin America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 71 Brazil Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 72 Brazil Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 73 Brazil Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 74 Mexico Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 75 Mexico Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 76 Mexico Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 77 Argentina Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 78 Argentina Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 79 Argentina Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 87 South Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 88 South Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 89 South Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 90 UAE Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 91 UAE Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 92 UAE Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
Table 94 Kuwait Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
Table 95 Kuwait Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Cancer Vaccine Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Cancer vaccine market: Vaccine Type outlook and key takeaways
Fig. 15 Cancer vaccine market: Vaccine Type movement analysis & market share 2022 & 2030
Fig. 16 Preventive cancer vaccine market, 2018 - 2030 (USD Million)
Fig. 17 Therapeutic cancer vaccine market, 2018 - 2030 (USD Million)
Fig. 18 Others market, 2018 - 2030 (USD Million)
Fig. 19 Cancer vaccine market: Indication type outlook and key takeaways
Fig. 20 Cancer vaccine market: Indication type movement analysis & market share 2022 & 2030
Fig. 21 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 22 Bladder cancer market, 2018 - 2030 (USD Million)
Fig. 23 Melanoma market, 2018 - 2030 (USD Million)
Fig. 24 Cervical cancer market, 2018 - 2030 (USD Million)
Fig. 25 Others market, 2018 - 2030 (USD Million)
Fig. 26 Cancer vaccine market: Technology type outlook and key takeaways
Fig. 27 Cancer vaccine market: Technology type movement analysis & market share 2022 & 2030
Fig. 28 Recombinant cancer vaccine market, 2018 - 2030 (USD Million)
Fig. 29 Whole-cell cancer vaccine market, 2018 - 2030 (USD Million)
Fig. 30 Viral vector and DNA cancer vaccine market, 2018 - 2030 (USD Million)
Fig. 31 Other technologies market, 2018 - 2030 (USD Million)
Fig. 32 Regional Marketplace: Key Takeaways
Fig. 33 Regional Outlook, 2022 & 2030
Fig. 34 Regional Market Dashboard
Fig. 35 Regional Market Place: Key Takeaways
Fig. 36 North America, SWOT Analysis
Fig. 37 Europe, SWOT Analysis
Fig. 38 Asia Pacific, SWOT Analysis
Fig. 39 Latin America, SWOT Analysis
Fig. 40 MEA, SWOT Analysis
Fig. 41 North America
Fig. 42 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 43 U.S. Key Country Dynamics
Fig. 44 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 45 Canada Key Country Dynamics
Fig. 46 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 47 Europe
Fig. 48 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 49 UK Key Country Dynamics
Fig. 50 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 51 Germany Key Country Dynamics
Fig. 52 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 53 France Key Country Dynamics
Fig. 54 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 55 Italy Key Country Dynamics
Fig. 56 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 57 Spain Key Country Dynamics
Fig. 58 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 59 Denmark Key Country Dynamics
Fig. 60 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 61 Sweden Key Country Dynamics
Fig. 62 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 63 Norway Key Country Dynamics
Fig. 64 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 65 Asia Pacific
Fig. 66 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 67 Japan Key Country Dynamics
Fig. 68 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 69 China Key Country Dynamics
Fig. 70 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 71 India Key Country Dynamics
Fig. 72 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 73 Australia Key Country Dynamics
Fig. 74 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 75 Thailand Key Country Dynamics
Fig. 76 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 77 South Korea Key Country Dynamics
Fig. 78 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 79 Latin America
Fig. 80 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 81 Brazil Key Country Dynamics
Fig. 82 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 83 Mexico Key Country Dynamics
Fig. 84 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 85 Argentina Key Country Dynamics
Fig. 86 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 87 MEA
Fig. 88 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 89 South Africa Key Country Dynamics
Fig. 90 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 91 Saudi Arabia Key Country Dynamics
Fig. 92 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 93 UAE Key Country Dynamics
Fig. 94 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 95 Kuwait Key Country Dynamics
Fig. 96 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 97 Strategy Mapping

Companies Mentioned

  • Merck & Co., Inc.
  • GSK plc
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies.
  • Ferring B.V.
  • Amgen, Inc.
  • Moderna, Inc.
  • Sanofi
  • AstraZeneca
  • Bristol-Myers Squibb Company

Methodology

Loading
LOADING...

Table Information